GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Joincare Pharmaceutical Group Industry Co 600380.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.55

+0.19%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥15.22bn

FY2016FY2025

Net income

CN¥1.34bn

FY2016FY2025

Free cash flow

CN¥3.12bn

FY2016FY2025

Shareholders' equity

CN¥15.18bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥15.22bnCN¥15.62bnCN¥16.65bnCN¥17.14bnCN¥15.90bnCN¥13.52bnCN¥11.98bnCN¥11.20bnCN¥10.78bnCN¥9.72bn
Gross profitCN¥9.50bnCN¥9.52bnCN¥10.04bnCN¥10.76bnCN¥10.13bnCN¥8.58bnCN¥7.66bnCN¥6.92bnCN¥6.73bnCN¥6.00bn
Research and developmentCN¥1.27bnCN¥1.44bnCN¥1.66bnCN¥1.74bnCN¥1.40bnCN¥1.07bnCN¥905.6mCN¥708.4mCN¥528.2mCN¥383.3m
Operating incomeCN¥3.19bnCN¥3.62bnCN¥3.51bnCN¥3.48bnCN¥2.98bnCN¥2.97bnCN¥2.19bnCN¥1.59bnCN¥1.42bnCN¥1.07bn
Net incomeCN¥1.34bnCN¥1.39bnCN¥1.44bnCN¥1.50bnCN¥1.33bnCN¥1.12bnCN¥894.3mCN¥699.4mCN¥2.13bnCN¥451.4m
Diluted earnings per share0.730.740.770.790.700.580.460.361.240.26

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥35.41bnCN¥35.72bnCN¥36.36bnCN¥35.73bnCN¥31.10bnCN¥28.16bnCN¥25.44bnCN¥24.99bnCN¥22.21bnCN¥16.07bn
Cash and short-term investments—CN¥14.94bnCN¥16.18bnCN¥14.92bnCN¥11.91bnCN¥12.32bnCN¥11.21bnCN¥11.49bnCN¥9.07bnCN¥2.95bn
Total liabilitiesCN¥11.05bnCN¥12.32bnCN¥13.72bnCN¥13.71bnCN¥10.92bnCN¥8.92bnCN¥8.05bnCN¥8.69bnCN¥8.59bnCN¥6.74bn
DebtCN¥1.57bnCN¥4.90bnCN¥5.21bnCN¥5.44bnCN¥3.46bnCN¥2.49bnCN¥2.68bnCN¥3.70bnCN¥2.66bnCN¥1.90bn
Shareholders' equityCN¥15.18bnCN¥14.53bnCN¥13.76bnCN¥13.12bnCN¥11.82bnCN¥11.10bnCN¥10.36bnCN¥9.64bnCN¥7.39bnCN¥5.38bn
Shares outstanding1,829m1,874m1,866m1,901m1,911m1,932m1,943m1,937m1,727m1,726m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥3.89bnCN¥3.64bnCN¥3.93bnCN¥3.98bnCN¥2.56bnCN¥3.02bnCN¥2.31bnCN¥1.83bnCN¥1.87bnCN¥1.64bn
Capital spending−CN¥767.2m−CN¥979.1m−CN¥1.13bn−CN¥1.15bn−CN¥1.52bn−CN¥830.4m−CN¥703.2m−CN¥655.0m−CN¥480.7m−CN¥500.0m
Free cash flowCN¥3.12bnCN¥2.66bnCN¥2.80bnCN¥2.83bnCN¥1.04bnCN¥2.19bnCN¥1.61bnCN¥1.17bnCN¥1.39bnCN¥1.14bn
Dividends paid−CN¥447.1m−CN¥468.1m−CN¥336.8m−CN¥277.6m−CN¥288.7m−CN¥308.4m−CN¥310.1m−CN¥446.5m−CN¥368.8m−CN¥319.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.86bnCN¥3.72bnCN¥3.74bnCN¥3.58bnCN¥3.81bnCN¥4.09bnCN¥3.72bnCN¥3.66bn
Gross profitCN¥1.51bnCN¥2.35bnCN¥2.28bnCN¥2.31bnCN¥2.37bnCN¥2.53bnCN¥2.02bnCN¥2.37bn
Operating incomeCN¥508.2mCN¥994.9mCN¥614.8mCN¥678.4mCN¥929.5mCN¥1.15bnCN¥783.9mCN¥845.5m
Net incomeCN¥232.7mCN¥415.0mCN¥244.3mCN¥306.3mCN¥349.2mCN¥435.8mCN¥275.0mCN¥335.1m
Diluted earnings per share0.130.230.130.170.190.240.150.18
Cash from operations———CN¥1.09bnCN¥1.12bnCN¥809.0m—CN¥890.0m
Capital spending−CN¥171.0m−CN¥171.0m−CN¥123.0m−CN¥155.0m−CN¥301.0m−CN¥187.0m−CN¥242.0m−CN¥202.0m
Free cash flow———CN¥935.0mCN¥815.0mCN¥622.0m—CN¥688.0m
Total assetsCN¥34.72bnCN¥35.48bnCN¥35.41bnCN¥36.01bnCN¥35.55bnCN¥35.77bnCN¥35.72bnCN¥36.17bn
Cash and short-term investments———CN¥15.72bnCN¥14.98bnCN¥14.94bnCN¥14.94bnCN¥14.67bn
DebtCN¥783.9mCN¥980.9mCN¥1.57bnCN¥4.12bnCN¥4.42bnCN¥4.86bnCN¥4.88bnCN¥3.42bn
Shareholders' equityCN¥15.22bnCN¥15.61bnCN¥15.18bnCN¥14.87bnCN¥14.65bnCN¥14.64bnCN¥14.53bnCN¥14.49bn

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin62.4%61.0%60.3%62.8%63.7%63.4%
Operating margin20.9%23.2%21.1%20.3%18.8%22.0%
Net margin8.8%8.9%8.7%8.8%8.4%8.3%
Return on equity8.8%9.5%10.5%11.5%11.2%10.1%
Return on assets3.8%3.9%4.0%4.2%4.3%4.0%
Free cash flow yield27.5%26.6%29.3%29.2%23.1%21.6%
Revenue growth-2.6%-6.2%-2.9%7.8%17.6%12.9%
Earnings growth-3.7%-3.9%-4.0%13.1%18.6%25.3%
Current ratio2.62x2.48x2.42x2.38x2.07x2.36x
Debt to equity0.10x0.34x0.38x0.41x0.55x0.22x
Equity ratio42.9%40.7%37.8%36.7%38.0%39.4%
Interest coverage36.60x26.17x22.67x23.59x30.97x70.37x
R&D as a share of sales8.4%9.2%10.0%10.2%8.8%7.9%
Buybacks as a share of market value2.4%-0.5%1.9%0.5%1.1%0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-3.9%2.4%5.8%
Operating income-2.9%1.4%13.9%
Net income-3.9%3.6%12.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin61.7%61.6%62.2%62.2%
Operating margin22.1%21.3%21.0%18.4%
Net margin8.8%8.8%8.6%8.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings15.815.216.114.318.524.022.518.58.234.4
Price to sales1.41.41.41.31.52.01.71.11.61.6

Dividends and splits

Per share, in the currency the company pays

Paid for 13 years. Last went ex-dividend on 26 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.220.200.180.180.150.150.160.16
  • 6-for-5 split · 16 May 2012
  • 6-for-5 split · 14 Apr 2010
  • 9-for-5 split · 24 Apr 2008
  • 1-to-1 reverse split · 24 Nov 2006
  • 3-for-2 split · 17 Nov 2003
  • 3-for-2 split · 3 Jun 2002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.